Voorspellers of clinically relevant bleeding during extended anticoagulation for cancer-associated VTE

In their study in The Lancet Haematology, Mahé and colleagues report a post-hoc analysis of the API-CAT randomised, double-blind, non-inferiority trial, identifying predictors of clinically relevant bleeding during 12 months of extended apixaban therapy in patients with active cancer who had completed at least 6 months of anticoagulation for venous thromboembolism (VTE).1 Among 1766 participants, clinically relevant bleeding occurred in 238 patients (cumulative incidence 13·9%), including 61 major bleeding events (3·6%).